October 18, 2018
Novocure Announces that the Medicare DME MACs Have Accepted the Local Coverage Determination Reconsideration Request for Optune®
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the durable medical equipment (DME) Medicare administrative contractors (MACs) have accepted our local coverage determination (LCD) reconsideration request for the treatment of newly diagnosed glioblastoma (GBM) and plan to take steps to publish a final LCD for newly diagnosed… Read More
learn more
October 4, 2018
Novocure Announces 55 Presentations at European Association of Neuro-Oncology Meeting 2018
Highlights include a data analysis of EF-14 that demonstrated an increased dose of Tumor Treating Fields to the tumor bed improved overall survival in GBM patients as well as safety data from a surveillance study ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today 55 presentations on Tumor… Read More
learn more
October 1, 2018
Novocure to Report Third Quarter 2018 Financial Results
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2018 on Thursday, October 25, 2018, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and… Read More
learn more
September 25, 2018
Data from STELLAR Registration Trial of Tumor Treating Fields in Mesothelioma to be Presented at the IASLC 19th World Conference on Lung Cancer
Mesothelioma patients who received Tumor Treating Fields with pemetrexed and cisplatin or carboplatin experienced median overall survival of 18.2 months compared to 12.1 months in historical control with no increase in systemic toxicity Data will be highlighted in an oral presentation at world’s largest meeting dedicated to lung… Read More
learn more
September 12, 2018
Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China
Zai Lab granted license to commercialize oncology platform technology Tumor Treating Fields, including the brand name Optune®, in China, Hong Kong, Macau and Taiwan Zai Lab will support enrollment of Chinese patients to certain clinical trials investigating Tumor Treating Fields, intended to accelerate clinical trial enrollment Tumor… Read More
learn more
September 5, 2018
Tumor Treating Fields Plus Standard of Care Chemotherapy Significantly Extends Median Overall Survival by 6.1 Months in STELLAR Phase 2 Registration Trial in Mesothelioma Compared to Historical Control
Mesothelioma patients who received Tumor Treating Fields with pemetrexed and cisplatin or carboplatin experienced median overall survival of 18.2 months compared to 12.1 months in historical control with no increase in systemic toxicity Results support the use of Tumor Treating Fields in first potential indication outside of the… Read More
learn more
August 15, 2018
Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer
US Oncology Research will open 10 clinical trial sites, enrolling patients in Novocure’s PANOVA-3 trial to test the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer ST. HELIER, Jersey & THE WOODLANDS, Texas–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) and… Read More
learn more
August 3, 2018
Novocure to Present at Two Upcoming Investor Conferences
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in two upcoming investor conferences. Wilco Groenhuysen, Novocure’s Chief Financial Officer, will participate in the 2018 Wedbush PacGrow Healthcare Conference on Aug. 15, 2018, in New York City. Mr. Groenhuysen’s presentation will begin at 12:45… Read More
learn more
August 2, 2018
Novocure Announces Addition to Its Board of Directors
Jeryl Hilleman, Chief Financial Officer of Intersect ENT, elected to board of directors ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Jeryl (Jeri) Hilleman, an experienced executive leader, was elected to Novocure’s board in July 2018. “We are… Read More
learn more
July 31, 2018
Gynecologic Oncology Publishes Results of the INNOVATE Phase 2 Pilot Study Demonstrating Combination of Tumor Treating Fields with Paclitaxel May Improve Survival of Patients with Recurrent Ovarian Cancer
Progression free survival of patients treated with Tumor Treating Fields plus weekly paclitaxel was more than double that of weekly paclitaxel-treated historical controls ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the results of its INNOVATE phase 2 pilot trial have been published in… Read More
learn more
